A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Recruiting now

Conditions studied: Prostatic Neoplasms, Castration-Resistant

In brief

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Key facts

Study ID

NCT07677267

Run by

Novartis Pharmaceuticals

People needed

1067

Starts

2026-06-30

Expected to finish

2026-11-30

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older, up to 115. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
• Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
• Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
• Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
• Age ≥18 years at index.

You may not qualify if…

• None.

Where it is running

• Novartis — East Hanover, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.